ATE430804T1 - Für eine prozessierungskomponente aus der n- terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid - Google Patents
Für eine prozessierungskomponente aus der n- terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptidInfo
- Publication number
- ATE430804T1 ATE430804T1 AT01916744T AT01916744T ATE430804T1 AT E430804 T1 ATE430804 T1 AT E430804T1 AT 01916744 T AT01916744 T AT 01916744T AT 01916744 T AT01916744 T AT 01916744T AT E430804 T1 ATE430804 T1 AT E430804T1
- Authority
- AT
- Austria
- Prior art keywords
- nucleic acid
- processing component
- acid construct
- terminal region
- hepatitis virus
- Prior art date
Links
- 102000039446 nucleic acids Human genes 0.000 title abstract 3
- 108020004707 nucleic acids Proteins 0.000 title abstract 3
- 150000007523 nucleic acids Chemical class 0.000 title abstract 3
- 229920001184 polypeptide Polymers 0.000 title abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 title abstract 3
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 3
- 101710159752 Poly(3-hydroxyalkanoate) polymerase subunit PhaE Proteins 0.000 title 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 title 1
- 241000700605 Viruses Species 0.000 title 1
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 208000006454 hepatitis Diseases 0.000 title 1
- 231100000283 hepatitis Toxicity 0.000 title 1
- 210000004897 n-terminal region Anatomy 0.000 title 1
- 230000000890 antigenic effect Effects 0.000 abstract 2
- 230000028993 immune response Effects 0.000 abstract 2
- 241000724675 Hepatitis E virus Species 0.000 abstract 1
- 108700001237 Nucleic Acid-Based Vaccines Proteins 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 108020001507 fusion proteins Proteins 0.000 abstract 1
- 102000037865 fusion proteins Human genes 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 229940023146 nucleic acid vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2730/00—Reverse transcribing DNA viruses
- C12N2730/00011—Details
- C12N2730/10011—Hepadnaviridae
- C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
- C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
- C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/28011—Hepeviridae
- C12N2770/28111—Hepevirus, e.g. hepatitis E virus
- C12N2770/28122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Transplantation (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AUPQ6616A AUPQ661600A0 (en) | 2000-03-31 | 2000-03-31 | A nucleic acid construct and methods related thereto |
| PCT/AU2001/000353 WO2001073078A1 (en) | 2000-03-31 | 2001-03-30 | A nucleic acid construct encoding a processing component derived from the n-terminal region of the hepatitis virus orf2, and an antigenic polypeptide |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE430804T1 true ATE430804T1 (de) | 2009-05-15 |
Family
ID=3820712
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT01916744T ATE430804T1 (de) | 2000-03-31 | 2001-03-30 | Für eine prozessierungskomponente aus der n- terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US7341723B2 (enExample) |
| EP (1) | EP1274851B1 (enExample) |
| JP (1) | JP2003528614A (enExample) |
| KR (1) | KR100768051B1 (enExample) |
| CN (1) | CN1426472A (enExample) |
| AT (1) | ATE430804T1 (enExample) |
| AU (1) | AUPQ661600A0 (enExample) |
| CA (1) | CA2407036A1 (enExample) |
| DE (1) | DE60138612D1 (enExample) |
| HK (1) | HK1052368A1 (enExample) |
| MX (1) | MXPA02009437A (enExample) |
| NZ (1) | NZ521758A (enExample) |
| WO (1) | WO2001073078A1 (enExample) |
| ZA (1) | ZA200207769B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2004004761A2 (en) | 2002-07-05 | 2004-01-15 | Denis Leclerc | Adjuvant viral particle |
| US8101189B2 (en) | 2002-07-05 | 2012-01-24 | Folia Biotech Inc. | Vaccines and immunopotentiating compositions and methods for making and using them |
| KR100641810B1 (ko) * | 2004-04-23 | 2006-11-06 | 주식회사 포스코건설 | 충격흡수 및 복원 가능한 중간 스프링 설치 금속재 지주 |
| US8906863B2 (en) | 2009-02-27 | 2014-12-09 | The Regents Of The University Of California | Proteolysis-resistant capsid of chimeric hepatitis E virus as an oral delivery vector |
| EP2400982B1 (en) * | 2009-02-27 | 2016-05-11 | The Regents of The University of California | Multiple antigen delivery system using hepatitis e virus-like particle |
| US8906862B2 (en) | 2009-02-27 | 2014-12-09 | The Regents Of The University Of California | Multiple antigen delivery system using hepatitis E virus-like particle |
-
2000
- 2000-03-31 AU AUPQ6616A patent/AUPQ661600A0/en not_active Abandoned
-
2001
- 2001-03-30 MX MXPA02009437A patent/MXPA02009437A/es unknown
- 2001-03-30 EP EP01916744A patent/EP1274851B1/en not_active Expired - Lifetime
- 2001-03-30 KR KR1020027013060A patent/KR100768051B1/ko not_active Expired - Fee Related
- 2001-03-30 CN CN01808764A patent/CN1426472A/zh active Pending
- 2001-03-30 NZ NZ521758A patent/NZ521758A/en unknown
- 2001-03-30 AT AT01916744T patent/ATE430804T1/de not_active IP Right Cessation
- 2001-03-30 HK HK03104476.2A patent/HK1052368A1/zh unknown
- 2001-03-30 WO PCT/AU2001/000353 patent/WO2001073078A1/en not_active Ceased
- 2001-03-30 JP JP2001570795A patent/JP2003528614A/ja not_active Withdrawn
- 2001-03-30 CA CA002407036A patent/CA2407036A1/en not_active Abandoned
- 2001-03-30 DE DE60138612T patent/DE60138612D1/de not_active Expired - Fee Related
-
2002
- 2002-09-26 ZA ZA200207769A patent/ZA200207769B/en unknown
- 2002-09-27 US US10/260,846 patent/US7341723B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| US7341723B2 (en) | 2008-03-11 |
| EP1274851B1 (en) | 2009-05-06 |
| EP1274851A1 (en) | 2003-01-15 |
| WO2001073078A1 (en) | 2001-10-04 |
| EP1274851A4 (en) | 2004-12-08 |
| HK1052368A1 (zh) | 2003-09-11 |
| DE60138612D1 (de) | 2009-06-18 |
| MXPA02009437A (es) | 2006-05-25 |
| KR100768051B1 (ko) | 2007-10-18 |
| KR20030015223A (ko) | 2003-02-20 |
| AUPQ661600A0 (en) | 2000-05-04 |
| CA2407036A1 (en) | 2001-10-04 |
| CN1426472A (zh) | 2003-06-25 |
| US20030158138A1 (en) | 2003-08-21 |
| ZA200207769B (en) | 2004-02-10 |
| JP2003528614A (ja) | 2003-09-30 |
| NZ521758A (en) | 2004-05-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE60117978D1 (de) | Modifizierung des hepatitis b kernantigens | |
| DE60232577D1 (de) | Oligomerische komplexe von chimären proteinen mit verbessertem immunogenen potential | |
| DK0835315T3 (da) | Vaccine til porcint reproduktivt og respiratorisk syndrom virus | |
| DK0414374T3 (da) | Hidtil ukendte antigener og fremgangsmåder til fremstilling deraf | |
| DK0561890T3 (da) | DNA ekspressionssystemer baseret på alphavira | |
| NZ545048A (en) | Chimeric antigens for breaking host tolerance to foreign antigens | |
| ATE359084T1 (de) | Modifizierter hitzeschockprotein/peptidantigen komplex | |
| Collen et al. | Heterotypic recognition of foot-and-mouth disease virus by cattle lymphocytes | |
| DE69936977D1 (de) | Durch polynukleinsäuren vom reproduktiven und respiratorischen syndromvirus des schweines kodierte proteine | |
| MXPA02006888A (es) | Flavivirus recombinantes y metodos para utilizar los mismos. | |
| DE69333468D1 (de) | Schützende antikörper induzierende antigene aus plasmodium falciparum | |
| IT1180160B (it) | Antigene di peptide protettivo | |
| ATE430804T1 (de) | Für eine prozessierungskomponente aus der n- terminalen region des hepatitis virus orf2 kodierendes nukleinsäurekonstrukt und antigenes polypeptid | |
| EP1015009A4 (en) | GENETIC MATERIAL IN THE FORM OF MITIGATED IMMUNIZATION CASSETTES BASED ON LIVER DNA FOR GENETIC VACCINES | |
| NO993468D0 (no) | Syntetiske peptid-epitoper fra proteinet fra Pre-M/M fra dengue-virus | |
| CN102168088A (zh) | T细胞免疫原基因ti及其在口蹄疫蛋白亚单位疫苗和灭活疫苗中的应用 | |
| EP0236977A3 (en) | Bovine virus diarrhea and hog cholera vaccines | |
| YU45292A (sh) | Različiti površinski proteini hepatitis b virusa koji obrazuju čestice | |
| NO20041564L (no) | Infeksios lakse anemi-virus vaksine | |
| DE50212580D1 (de) | Rekombinantes mva mit der fähigkeit zur expression von hcv struktur-antigenen | |
| WO2002051237A3 (en) | Helicobacter proteins, nucleic acids and uses thereof | |
| DE3776034D1 (de) | Vakzine. | |
| DK0691404T3 (da) | Vaccine til immunisering mod TBE-virusinfektioner samt en fremgangsmåde til fremstilling deraf | |
| JP2003528614A5 (enExample) | ||
| KR890008318A (ko) | 플라스모듐 팔시파룸의 재조합 히스티딘-고함유 단백질, 이의 제조방법 및 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |